We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

“This is not a zero-sum game with the biologics in the treatment of moderate to severe atopic dermatitis,” said Bourla. These patients currently rely on biologic drugs like Sanofi and ...

Patients with atopic dermatitis had an increased risk for COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.

A phase 3 trial shows that ivarmacitinib improves symptoms in adults with moderate to severe atopic dermatitis compared with ...

The phase 2b trial compared four doses of temtokibart to placebo in 262 adults with moderate to severe atopic dermatitis, the ...

Regeneron Pharmaceuticals (REGN ... several of which have been shown to co-morbidly occur with CSU, such as atopic dermatitis and asthma – providing patients with one treatment that might ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $3.25 billion, while the ...

Regeneron has leveraged its monoclonal antibody ... Immunology drug Dupixent is seeing very strong, steady growth in atopic dermatitis and asthma, and approvals continue to expend to new ...